Regeneron Pharmaceuticals’ (REGN) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report issued on Tuesday, Benzinga reports. Royal Bank of Canada currently has a $1,282.00 price objective on the biopharmaceutical company’s stock.

REGN has been the subject of several other reports. Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an overweight rating in a research note on Friday, August 2nd. TD Cowen increased their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a buy rating in a research report on Tuesday, July 23rd. StockNews.com raised shares of Regeneron Pharmaceuticals from a buy rating to a strong-buy rating in a report on Tuesday, September 10th. JPMorgan Chase & Co. increased their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an overweight rating in a report on Friday, August 2nd. Finally, Cantor Fitzgerald restated a neutral rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday. One analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus target price of $1,111.30.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $1,146.75 on Tuesday. Regeneron Pharmaceuticals has a 1-year low of $769.19 and a 1-year high of $1,211.20. The company has a market cap of $126.36 billion, a price-to-earnings ratio of 33.88, a PEG ratio of 3.97 and a beta of 0.12. The company’s fifty day moving average price is $1,128.09 and its two-hundred day moving average price is $1,028.93. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the previous year, the firm posted $8.79 earnings per share. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The disclosure for this sale can be found here. Insiders sold 10,026 shares of company stock valued at $11,498,705 over the last ninety days. 7.48% of the stock is currently owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in REGN. Brown Lisle Cummings Inc. increased its position in shares of Regeneron Pharmaceuticals by 18.2% during the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 10 shares during the period. Sachetta LLC lifted its stake in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Team Hewins LLC lifted its stake in Regeneron Pharmaceuticals by 2.5% in the 1st quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 11 shares in the last quarter. Angeles Wealth Management LLC boosted its holdings in Regeneron Pharmaceuticals by 3.5% in the 1st quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock valued at $313,000 after purchasing an additional 11 shares during the period. Finally, TrinityPoint Wealth LLC grew its position in shares of Regeneron Pharmaceuticals by 4.8% during the 4th quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 12 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.